Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 5/20 | 0.48 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 3/20 | 0.44 |
| ▸ | MET | P08581 | 3/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29539635 | 1.00 | PDK2 (0.48) | PDK2FEN1SCDMETKIT | |
| SCHEMBL26354200 | 0.81 | PIM1 (0.56) | PDK2FEN1METKITIKBKE | |
| SCHEMBL26352017 | 0.80 | PIM1 (0.55) | PDK2FEN1METKITFGFR1 | |
| SCHEMBL25946710 | 0.80 | PDK2 (0.41) | PDK2FEN1METKITIKBKE | |
| SCHEMBL16561177 | 0.77 | MKNK1 (0.51) | METFGFR3KDRTGFBR1PIM1 | |
| SCHEMBL320451 | 0.76 | TGFBR1 (0.53) | PDK2FEN1METIKBKETBK1 | |
| SCHEMBL320352 | 0.74 | FEN1 (0.49) | PDK2FEN1METFGFR1FGFR3 | |
| SCHEMBL320657 | 0.72 | TGFBR1 (0.51) | PDK2FEN1METIKBKETBK1 | |
| SCHEMBL574061 | 0.72 | AXL (0.48) | FEN1METKITIKBKETBK1 | |
| SCHEMBL27174578 | 0.72 | MET (0.51) | SCDMETKDRTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092774-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-03-21 | — | — | US | disclosed |
| WO-2023125812-A1 | SUBSTITUTED PYRIMIDONE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2022057895-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2022-03-24 | — | — | WO | disclosed |
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092774-A1 | HETEROAROMATIC COMPOUNDS AND USES THEREOF | CYP2D6, CYP3A7, CYP2F1 | PDK2 757/4885FEN1 3438/4885SCD 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.